Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
554 Leser
Artikel bewerten:
(2)

Goodbody Health Inc.: Goodbody Health Announces the Launch of Its Core Health Diagnostic Check

VANCOUVER, BC / ACCESSWIRE / May 26, 2022 / Goodbody Health Inc. (CSE:GDBY) (OTCQB:GDBYF) ("Goodbody Health" or the "Company") is pleased to announce that, it has launched its core UK Health check which offers a comprehensive summary of a person's health. Keenly priced at £99, this new test includes innovative in-clinic diabetes and cholesterol tests, with results finalised in minutes. These tests determine a person's risk for developing cardiac health problems or diabetes over the next 10 years. Consistent with our value of 'Know More - Live Better", knowing more about one's current wellness empowers the individual to take better control of their health.

Goodbody products and services are focussed on prevention and will help alleviate the pressures on the NHS in line with the NHS long term plan. We are launching to coincide with Type 2 Diabetes prevention week, highlighting 1 in 15 people in the UK has diabetes according to Diabetes UK https://www.diabetes.org.uk/diabetes-the-basics and 1 million people who have type 2 diabetes that have not yet been diagnosed.

This health check, alongside our other diagnostic tests, will start as a trial in a number of chosen pharmacies and our own stores based in Bath and Bristol before rapidly being rolled out nationally. It will be provided within Goodbody's nationwide distribution network of community pharmacies and supported with marketing materials and activities to drive traffic and increase footfall into pharmacies. The UK population is 67 million and an estimated 95% will visit a pharmacy at least once a year meaning a potential 63.7 million customers.

https://www.rsph.org.uk/resourceLibrary/reducing-premature-mortality-the-role-of-community-pharmacies-.html

Geremy Thomas, Executive Chairman, said: "We are very excited about the launch of this core health care product. The recent pandemic has made us all realise that our health is our most important asset, there has never been a better time to take control of your current health. With a number of clinics already on board and the testing available using new, innovative technology, our developing network will soon be able to offer the health check as an additional product within their pharmacy".

The Directors of the Company accept responsibility for the contents of this announcement.

On behalf of the Board of Directors,

Marc Howells
Chief Executive Officer
Goodbody Health Inc.
+44 (0) 20 7971 1255
enquiries@goodbodyhealth.com
www.goodbodyhealth.com

Anne Tew
Chief Financial Officer
Goodbody Health Inc.
+44 (0) 20 7971 1255
enquiries@goodbodyhealth.com
www.goodbodyhealth.com

Neither the Canadian Securities Exchange nor its Market Regulator (as defined in the policies of the Canadian Securities Exchange) accept responsibility for the adequacy or accuracy of this release. This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Goodbody Health's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" "plan is" or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur", "will be achieved" or "shortly". The forward-looking information and forward-looking statements contained herein include, but are not limited to: there is no guarantee that the price of £99 is a keen price; the test will be rapidly rolled out nationally; marketing materials and activities will drive traffic and increase footfall into pharmacies; the developing network will soon be able to offer the health check as an additional product within their pharmacy.

Although Goodbody Health believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. In particular, Goodbody products and services will help alleviate the pressures on the NHS in line with the NHS long term plan; that there has never been a better time to take control of your current health.

Goodbody Health does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

SOURCE: Goodbody Health Inc.



View source version on accesswire.com:
https://www.accesswire.com/702654/Goodbody-Health-Announces-the-Launch-of-Its-Core-Health-Diagnostic-Check

© 2022 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.